



Dr. K S SACHDEVA

*Dy. Director General
Head, Central TB Division
Project Director, RNTCP*



सत्यमेव जयते

Tel. : 011-2306 3226
011-2306 2980
E-mail : ddtb@rntcp.org

भारत सरकार
Government of India

स्वास्थ्य एवं परिवार कल्याण मंत्रालय
Ministry of Health & Family Welfare
निर्माण भवन, नई दिल्ली-110108
Nirman Bhavan, New Delhi-110108

D. O. No z-28015/27/2012-TB (Part III)
date: 09/03/2020

The National TB Elimination Programme (NTEP) has adopted the evidence based all oral longer regimen for RR/MDR TB patients as communicated via DO letter z-28015/27/2012-TB (Part III) dated 21.01.2020. Once the Guidelines for PMDT in India 2019 (Pre-final Text) is implemented in the State/UTs, all longer regimens for treatment of RR/MDR/XDR TB with or without new drugs available under Guideline for PMDT in India (2017) are no longer available and should offer only 2 regimens for the MDR RRTB patients as follows:

1. Shorter MDRTB regimen
2. All oral longer MDRTB regimen

Based on the resistant pattern of the patient or due to the reasons associated with intolerability, the all oral longer MDR-TB regimen needs to be modified in accordance to the updated Guideline for PMDT in India 2019 (Prefinal Text). As per the general principle laid in this guideline, a patient should be treated with an all oral longer regimen composed of 5 and 4 drugs during Intensive phase (IP) and Continuation Phase (CP) respectively. The appropriate modification in composition of regimen should be carried out as per the table of sequence of using replacement drugs to modify all oral longer regimen as available in guideline.

The State/UTs are requested to assess the requirement of replacement drugs (Pyrazinamide, Amikacin, Ethionamide, PAS and Ethambutol) for the states and send the request to CTD to ensure the availability of replacement drugs at all Districts to ensure the appropriate management of DR TB patients.

(Dr. K. S. Sachdeva)

To,
STOs (All States & UTs) & DTO (All districts)
Nodal officers of DR TBC, Nodal/District DR TBC (All states)

Copy of information to:

1. PPS to Jt. Secretary (Public Health), MOHFW, GOI
2. All National Reference Laboratories (NRLs), Intermediate Reference Laboratories (IRLs) and Culture and DST laboratories (C-DST labs)
3. All State TB Training Demonstration Centre (STDC) Directors
4. WHO NTEP Regional Team Leads (RTL), State HQ & field consultants